Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma
The purpose of this study is to assess the overall response rate (ORR) of persistent, recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.
Cancer
DRUG: ARQ 501
The purpose of this study is to assess the overall response rate (ORR) of persistent, recurrent or metastatic leiomyosarcoma in patients treated with ARQ 501.